Pathophysiology of irritable bowel syndrome

被引:488
作者
Holtmann, Gerald J. [1 ,2 ]
Ford, Alexander C. [3 ,4 ]
Talley, Nicholas J. [5 ,6 ]
机构
[1] Univ Queensland, Princess Alexandra Hosp Brisbane, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia
[2] Univ Queensland, Translat Res Inst, Brisbane, Qld, Australia
[3] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds, W Yorkshire, England
[4] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England
[5] Univ Newcastle, Fac Hlth & Med, New Lambton Hts, NSW, Australia
[6] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
关键词
D O I
10.1016/S2468-1253(16)30023-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Traditionally, irritable bowel syndrome has been considered to be a disorder with no known underlying structural or biochemical explanation, but this concept is likely to be outdated. In this Review we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut disorder. There is epidemiological evidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do incident mood disorders occur. Additionally, possible mechanisms for gut-brain dysfunction have been identified, suggesting primary gut disturbances might be the underlying cause in a subgroup. Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity. An approach based on the underlying pathophysiology could help to develop therapies that target causes and ultimately provide a cure for patients with irritable bowel syndrome.
引用
收藏
页码:133 / 146
页数:14
相关论文
共 135 条
[81]
Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: Results 3 years after gastroenteritis [J].
Mearin, Fermin ;
Perello, Antonia ;
Balboa, Agustin ;
Perona, Monica ;
Sans, Miquel ;
Salas, Antonio ;
Angulo, Sandra ;
Lloreta, Josep ;
Benasayag, Ruth ;
Asuncion Garcia-Gonzalez, Maria ;
Perez-Oliveras, Marc ;
Coderch, Jordi .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (10) :1173-1185
[82]
Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients [J].
Mikocka-Walus, Antonina ;
Turnbull, Deborah ;
Moulding, Nicole ;
Wilson, Ian ;
Andrews, Jane M. ;
Holtmann, Gerald .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (07) :1137-1143
[83]
Differential Effects of FODMAPs (Fermentable Oligo-, Di-, Mono-Saccharides and Polyols) on Small and Large Intestinal Contents in Healthy Subjects Shown by MRI [J].
Murray, Kathryn ;
Wilkinson-Smith, Victoria ;
Hoad, Caroline ;
Costigan, Carolyn ;
Cox, Eleanor ;
Lam, Ching ;
Marciani, Luca ;
Gowland, Penny ;
Spiller, Robin C. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (01) :110-119
[84]
B-cell activation in patients with irritable bowel syndrome (IBS) [J].
Ohman, L. ;
Lindmark, A. -C. ;
Isaksson, S. ;
Posserud, I. ;
Strid, H. ;
Sjovall, H. ;
Simren, M. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (06) :644-e27
[85]
Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity [J].
Park, S. H. ;
Videlock, E. J. ;
Shih, W. ;
Presson, A. P. ;
Mayer, E. A. ;
Chang, L. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 28 (08) :1252-1260
[86]
Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating [J].
Patel, P. ;
Bercik, P. ;
Morgan, D. G. ;
Bolino, C. ;
Pintos-Sanchez, M. I. ;
Moayyedi, P. ;
Ford, A. C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (05) :449-458
[87]
Peery AF, 2015, GASTROENTEROLOGY, V149, P1731, DOI [10.1053/j.gastro.2015.08.045, 10.1053/j.gastro.2018.08.063]
[88]
Thicker Posterior Insula Is Associated With Disease Duration in Women With Irritable Bowel Syndrome (IBS) Whereas Thicker Orbitofrontal Cortex Predicts Reduced Pain Inhibition in Both IBS Patients and Controls [J].
Piche, Mathieu ;
Chen, Jen-I ;
Roy, Mathieu ;
Poitras, Pierre ;
Bouin, Mickael ;
Rainville, Pierre .
JOURNAL OF PAIN, 2013, 14 (10) :1217-1226
[89]
Pimentel M, 2000, AM J GASTROENTEROL, V95, P3503, DOI 10.1111/j.1572-0241.2000.03368.x
[90]
The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome - A randomized trial [J].
Pimentel, Mark ;
Park, Sandy ;
Mirocha, James ;
Kane, Sunanda V. ;
Kong, Yuthana .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (08) :557-563